Corvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS

Simply Wall St.05-12

In early May 2026, Corvus Pharmaceuticals reported a first-quarter 2026 net loss of US$13.69 million, reversing from net income a year earlier, while also filing a US$46.16 million shelf registration ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634626890?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-05-12 08:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634626890","market":"us","top_or_hot":-1,"title":"Corvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS","media":"Simply Wall St.","content":"<div>\n<p>In early May 2026, Corvus Pharmaceuticals reported a first-quarter 2026 net loss of US$13.69 million, reversing from net income a year earlier, while also filing a US$46.16 million shelf registration ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/corvus-loss-shelf-offering-and-soquelitinib-progress-might-c\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-12 08:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/corvus-loss-shelf-offering-and-soquelitinib-progress-might-c><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In early May 2026, Corvus Pharmaceuticals reported a first-quarter 2026 net loss of US$13.69 million, reversing from net income a year earlier, while also filing a US$46.16 million shelf registration ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/corvus-loss-shelf-offering-and-soquelitinib-progress-might-c\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/corvus-loss-shelf-offering-and-soquelitinib-progress-might-c","article_id":"2634626890","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/corvus-loss-shelf-offering-and-soquelitinib-progress-might-c","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2634626890","pubTimestamp":1778545953,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In early May 2026, Corvus Pharmaceuticals reported a first-quarter 2026 net loss of US$13.69 million, reversing from net income a year earlier, while also filing a US$46.16 million shelf registration for nearly 2,987,865 shares related to its employee stock ownership plan.\nAt the same time, the company highlighted positive clinical progress for its lead ITK inhibitor soquelitinib across multiple immune and oncology indications, supported by a cash position that management expects will fund...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","CRVS":"Corvus Pharmaceuticals, Inc.","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4097":"系统软件","PRGS":"Progress Software Corporation","BK4139":"生物科技"},"translate_title":"Corvus的损失、搁置发行和Soquelitinib的进展可能会改变投资CRV的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1.5,"CRVS":1.5},"content_text":"In early May 2026, Corvus Pharmaceuticals reported a first-quarter 2026 net loss of US$13.69 million, reversing from net income a year earlier, while also filing a US$46.16 million shelf registration for nearly 2,987,865 shares related to its employee stock ownership plan. At the same time, the company highlighted positive clinical progress for its lead ITK inhibitor soquelitinib across multiple immune and oncology indications, supported by a cash position that management expects will fund operations into the second quarter of 2028. We’ll now examine how the extended cash runway and advancing soquelitinib programs may reshape Corvus Pharmaceuticals’ longer-term investment narrative. AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementCorvus Pharmaceuticals Investment Narrative RecapTo own Corvus Pharmaceuticals, you need to believe that soquelitinib can translate its early immune and oncology data into successful late stage trials and, ultimately, commercial products, while the company manages its cash and dilution carefully. The latest results, with a Q1 2026 net loss and a cash runway guided into the second quarter of 2028, leave the core near term catalyst and risk largely unchanged: outcomes from the registrational PTCL trial and the Phase 2 atopic dermatitis program. The new US$46.16 million shelf registration tied to the employee stock ownership plan sits alongside the much larger cash balance from earlier financings and, in itself, does not shift the clinical risk profile. What matters more for the story is the continued advancement of soquelitinib into Phase 2 for atopic dermatitis and the ongoing Phase 3 PTCL study, since those readouts are still the key potential drivers of Corvus’ future business value. Yet, investors should still be aware that any setback in the PTCL Phase 3 trial could... Read the full narrative on Corvus Pharmaceuticals (it's free!)Corvus Pharmaceuticals' narrative projects $59.3 million revenue and $6.5 million earnings by 2029. This requires an earnings increase of about $21.6 million from -$15.1 million today.Uncover how Corvus Pharmaceuticals' forecasts yield a $35.00 fair value, a 121% upside to its current price.Exploring Other PerspectivesCRVS 1-Year Stock Price Chart Before this update, the most optimistic analysts were assuming about US$96.0 million of revenue and US$5.8 million of earnings by 2029, which is far more bullish than the consensus view and leans heavily on the same late stage soquelitinib PTCL program that now looks even more pivotal after Corvus highlighted funding into 2028.Explore 3 other fair value estimates on Corvus Pharmaceuticals - why the stock might be worth just $33.33!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Corvus Pharmaceuticals research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.Our free Corvus Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Corvus Pharmaceuticals' overall financial health at a glance.Looking For Alternative Opportunities?Our daily scans reveal stocks with breakout potential. Don't miss this chance:We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Uncover the next big thing with 26 elite penny stocks that balance risk and reward.The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634626890","isCrawlerRequest":true}